Psychiatry researcher steps down

Written byBob Grant

| 2 min read

Embattled Stanford psychiatrist and president-elect of the American Psychiatric Association, linkurl:Alan Schatzberg,;http://www.stanford.edu/group/adolescent.ctr/Research/schatzberg.html has resigned leadership of an NIH-funded research project studying the effects of mifepristone (also known as linkurl:RU-486);http://www.the-scientist.com/article/display/10905/ on patients with depression. The drug is made by Corcept Therapeutics, a company which Schatzberg co-founded, and in which he owns more than $6 million in stocks. His financial conflicts of interest have been linkurl:scrutinized;http://www.the-scientist.com/blog/display/54771/ for several months by Senator Charles Grassley (R-IA). Schatzberg is also the chair of the department of psychiatry at the Stanford University School of Medicine. According to linkurl:__The Stanford Daily__,;http://daily.stanford.edu/article/2008/8/14/profStepsDownAfterConflict university officials call Schatzberg's exit from the project, which was run on grants from the NIH's National Institute of Mental Health (NIMH), "temporary." Grassley first called attention to Schatzberg's apparent conflicts about six months ago, and the Senator has pursued the issue in several letters sent to Stanford administrators. Though Stanford University officials claim that Schatzberg fully disclosed the fact that he owned Corcept stock prior to beginning the project, Grassley insisted that the psychiatrist's research was in conflict with his financial ties to the company. "This equity could grow dramatically if the results of Dr. Schatzberg's government-sponsored research find that mifepristone could be used to treat psychotic major depression," Grassley wrote in a July 31 letter to Stanford president linkurl:John Hennessy.;http://www.stanford.edu/dept/president/biography/ In a linkurl:reply;http://ucomm.stanford.edu/news/073108_grassley.pdf to Grassley's inquiries about Schatzberg dated July 31, Stanford vice provost and dean of research Ann Arvin, wrote in a letter to the Senator that the university was taking measures to ameliorate the apparent conflict of interest surrounding Schatzberg. "Despite our belief that Stanford, NIMH, and Dr. Schatzberg have handled this grant in accordance with the regulations and applicable policies and with due regard for the integrity of the research, we can see how having Dr. Schatzberg continue as Principal Investigator on the grant can create an appearance of conflict of interest," she wrote. "Therefore Stanford University, with the concurrence of Dr. Schatzberg, is temporarily appointing another Principal Investigator on this grant and we have so advised NIMH." A Stanford spokesperson told __The Daily__ that linkurl:Fredric Kraemer,;http://med.stanford.edu/profiles/Fredric_Kraemer/ a cell biologist in Stanford's School of Medicine, will be filling in for Schatzberg on the project. Grassley continues to press the university on its own financial ties to Corcept and has asked Stanford officials to fully disclose the school's connections to the company. I have the feeling this story is far from over.

Meet the Author

Bob Grant

From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

View Full Profile

Psychiatry researcher steps down

The Scientist ARCHIVES

Become a Member of

Related Topics

Meet the Author

Bob Grant

Related Research Resources

Wooden Neurons: An Artistic Vision of the Brain

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Driving Innovation with Cell Culture Essentials

Driving Innovation with Cell Culture Essentials

Exploring the Inflammatory Tumor Microenvironment

A Comprehensive Guide to Next-Generation Sequencing

Products

Product News

BRANDTECH® Scientific Announces Strategic Partnership with Copia Scientific to Strengthen Sales and Service of the BRAND® Liquid Handling Station (LHS)

Enter Our 2026 Top Innovations Contest

Biotium Expands Tyramide Signal Amplification Portfolio with Brighter and More Stable Dyes for Enhanced Spatial Imaging

LabVantage Solutions Awarded $22.3 Million U.S Customs and Border Protection Contract to Deliver Next-Generation Forensic LIMS